MESACUP BP230 TEST

IVD-In Vitro Diagnostic Use CE marked

Instructions for use

The MESACUP BP230 TEST is a semi-quantitative enzyme-linked immunosorbent assay (ELISA) for the detection of anti BP230 antibodies in human serum.

Background:

Bullous pemphigoid (BP) is chronic itchy blistering disorder found mainly in aged person, characterized by frequent occurring of tense blister and erythema. IgG anti-basement membrane zone (BMZ) antibodies are found in the serum of patients, and linear IgG or C3 sediment is found on the basement membrane zone of the lesion. Target antigens of the autoantibodies in BP patient serum are BP180 and BP230, also called BPAG1 and BPAG2. Molecular weight of these antigens is 230 kD and 180 kD respectively. Anti-BP180 is thought to be the pathogenic autoantibody, however, not all BP patients have anti-BP180 antibody in their serum. Anti-BP230 antibody is also highly specific to BP and considered to be a useful serologic marker of the disease.
The MESACUP BP230 TEST has recombinant protein of both N-terminus and C-terminus of BP230 as solid phase and measures anti-BP230 autoantibodies in patient serum specifically

Principle:

The MESACUP BP230 TEST measures anti-BP230 antibodies present in the serum by ELISA. Calibrators and patient sera are added to microwell coated with BP230 antigen, allowing anti-BP230 antibodies to react with the immobilized antigen (Sample incubation). After washing to remove any unbound serum proteins, horseradish peroxidase conjugated anti-human IgG antibody is added and incubated (Conjugate incubation). Following another washing step, the peroxidase substrate is added and incubated for an additional period of time (Substrate incubation). Acid solution is then added to each well to terminate the enzyme reaction and to stabilize the color development. The assay can be quantified by measuring the reaction photometrically.

Size: 48 wells

Method: ELISA

Antigen: recombinant purified BP230-N and BP230C

Availability: all regions